The Jardiance jingle probably rings through your head for several hours after you watch the ad, and that's the point. You remember the ad for "the little pill with a big story to tell." Last year's ad ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

Hello Health Rounds Readers! Today we have three studies presented at medical meetings, including one testing a device that ...

The FDA rejected sotagliflozin 5 years ago for the same indication but for the broader population of adults with T1D, due to ...

While dapagliflozin (Farxiga) and empagliflozin (Jardiance) are approved for CKD in adults at risk of progression -- an ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...

David J. Phillip/AP The list includes medications for type 2 diabetes, allergic diseases, chronic kidney disease, heart ...

Elixir Medical's DynamX bioadaptor, introduced as a potential game-changer in heart artery treatments, adapts over time to restore the artery's natural motion. A study showed it leads to fewer ...

After many months of closely watched negotiations, the Centers for Medicare & Medicaid Services (CMS) announced the list of negotiated prices for 10 drugs. This marks the first set of negotiations ...

Lexicon's Inpefa faces fierce competition from established SGLT2 inhibitors, like Farxiga and Jardiance, making market penetration difficult. Inpefa’s early commercial results are underwhelming ...